Inovio Pharmaceuticals Inc INO.OQ INO.O is expected to show a fall in quarterly revenue when it reports results on March 12 for the period ending December 31 2025
LSEG's mean analyst estimate for Inovio Pharmaceuticals Inc is for a loss of 36 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Inovio Pharmaceuticals Inc is $10.00, about 478% above its last closing price of $1.73
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.41 | -0.42 | -0.87 | Missed | -105.6 |
Jun. 30 2025 | -0.60 | -0.61 | -0.61 | Met | -0.1 |
Mar. 31 2025 | -0.75 | -0.74 | -0.41 | Beat | 44.4 |
Dec. 31 2024 | -0.79 | -0.84 | -0.60 | Beat | 28.3 |
Sep. 30 2024 | -1.14 | -1.15 | -0.89 | Beat | 22.6 |
Jun. 30 2024 | -1.12 | -1.10 | -1.19 | Missed | -8 |
Mar. 31 2024 | -1.01 | -1.00 | -1.31 | Missed | -30.6 |
Dec. 31 2023 | -1.42 | -1.27 | -1.12 | Beat | 11.6 |
This summary was machine generated March 10 at 20:45 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments